Australia markets open in 1 hour 45 minutes
  • ALL ORDS

    7,107.10
    +56.10 (+0.80%)
     
  • AUD/USD

    0.7765
    +0.0015 (+0.19%)
     
  • ASX 200

    6,823.70
    +53.30 (+0.79%)
     
  • OIL

    53.01
    -0.30 (-0.56%)
     
  • GOLD

    1,870.30
    +3.80 (+0.20%)
     
  • BTC-AUD

    41,228.44
    -3,844.34 (-8.53%)
     
  • CMC Crypto 200

    635.18
    -44.72 (-6.58%)
     

Global Hemophilia Market 2020-2024 by Treatment Regimen, Type & Therapy - Insights & Forecast with Potential Impact of COVID-19 - ResearchAndMarkets.com

·4-min read

The "Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

The global hemophilia market is anticipated to reach US$13.86 billion in 2024, growing at a CAGR of 5.61% during the period spanning 2020-2024.

The growth in the market has been driven by factors like increasing healthcare expenditure and surging identified hemophilia patient volume. The market is expected to face certain challenges such as the high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like the development of novel hemophilia treatments and rising popularity of gene therapy.

The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2019, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2019.

The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2019 was held by replacement therapy segment. The global hemophilia market by region can be segmented into the following regions: North America, Europe and the Asia Pacific.

In 2019, the dominant share of the market was held by North America, followed by Europe and the Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards the growth in the North American market.

Key Topics Covered:

1. Market Overview

1.1 Hemophilia

1.2 Types of Hemophilia

1.3 Signs & Symptoms

1.4 Diagnosis of Hemophilia

1.5 Treatment of Hemophilia

2. Impact of COVID-19

2.1 Impact on Global Economy

2.2 Global Prevalence of COVID-19

2.3 Impact on Healthcare Spending

3. Global Market Analysis

3.1 Global Hemophilia Market by Value

3.2 Global Hemophilia Market Forecast by Value

3.3 Global Hemophilia Market by Treatment Regimen

3.4 Global Hemophilia Market by Type

3.4.1 Global Hemophilia A Market Forecast by Value

3.4.2 Global Hemophilia A Market by Severity

3.4.3 Global Hemophilia A Market by Treatment Type

3.4.4 Global Hemophilia A Market by Treatment Regimen

3.4.5 Global Hemophilia A Market Value by Treatment Regimen

3.4.6 Global Hemophilia B Market Forecast by Value

3.4.7 Global Hemophilia B Market by Severity

3.4.8 Global Hemophilia B Market by Treatment Type

3.4.9 Global Hemophilia B Market by Treatment Regimen

3.4.10 Global Hemophilia B Market Value by Treatment Regimen

3.5 Global Hemophilia Market by Therapy

3.5.1 Global Hemophilia Replacement Therapy Market Forecast by Value

3.5.2 Global Hemophilia ITI Therapy Market Forecast by Value

3.6 Global Hemophilia Market by Region

4. Regional Market Analysis

5. Market Dynamics

5.1 Growth Drivers

5.1.1 Increased Focus on Prophylactic Treatment

5.1.2 Increasing Diagnosis Rate

5.1.3 Rise in Global Healthcare Expenditure

5.2 Key Trends & Development

5.2.1 Shifting Focus to Extended Half Life Therapies

5.2.2 Development of Novel Hemophilia Treatments

5.2.3 Popularity of Gene Therapy

5.3 Challenges

5.3.1 High Cost of Treatment

5.3.2 Reluctance to Switch to New Therapies

6. Competitive Landscape

6.1 Global Market

6.1.1 Revenue Comparison - Key Players

6.1.2 Market Capitalization Comparison - Key Players

6.1.3 Research & Development Expenses Comparison - Key Players

6.1.4 Global Hemophilia A Market Share by Company

6.1.5 Global Hemophilia A Factor VIII Products Market Share by Company

6.1.6 Global Hemophilia A FVIII Gene Therapy Market Share Forecast

6.1.7 Global Hemophilia B Market Share by Company

6.1.8 Global Hemophilia B Factor IX Products Market Share Forecast

6.1.9 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast

6.1.10 Key Players - Major Anti-Hemophilia Products

6.2 The US Market

6.2.1 The US Hemophilia A Market Share by Company

6.3 Europe Market

6.3.1 Europe Hemophilia A Market Share by Company

7. Company Profiles

7.1 Pfizer Inc.

7.1.1 Business Overview

7.1.2 Financial Overview

7.1.3 Business Strategies

7.2 Bayer Group

7.3 Sanofi S.A.

7.4 Takeda Pharmaceutical Company

7.5 Novo Nordisk

7.6 CSL Limited

For more information about this report visit https://www.researchandmarkets.com/r/9q5ln2

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005722/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900